Q4 Earnings Estimate for TRDA Issued By Roth Capital

Entrada Therapeutics, Inc. (NASDAQ:TRDA) – Roth Capital issued their Q4 2026 earnings per share (EPS) estimates for Entrada Therapeutics in a report issued on Friday, February 28th. Roth Capital analyst B. Pachaiyappan expects that the company will post earnings of ($0.86) per share for the quarter. Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Entrada Therapeutics’ current full-year earnings is $1.12 per share.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings results on Thursday, February 27th. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.69. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. The business had revenue of $12.25 million for the quarter, compared to analysts’ expectations of $11.95 million.

TRDA has been the subject of a number of other reports. Roth Mkm assumed coverage on Entrada Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $29.00 price objective for the company. Oppenheimer increased their price objective on Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a report on Wednesday, November 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Entrada Therapeutics in a report on Tuesday, February 25th.

Entrada Therapeutics Price Performance

Shares of TRDA stock opened at $10.99 on Monday. Entrada Therapeutics has a 12-month low of $10.80 and a 12-month high of $21.79. The firm has a market capitalization of $411.25 million, a price-to-earnings ratio of 6.91 and a beta of -0.17. The business has a 50 day simple moving average of $14.06 and a 200 day simple moving average of $16.18.

Hedge Funds Weigh In On Entrada Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mackenzie Financial Corp bought a new position in Entrada Therapeutics during the 4th quarter valued at $251,000. WCG Wealth Advisors LLC lifted its position in shares of Entrada Therapeutics by 6.2% during the 4th quarter. WCG Wealth Advisors LLC now owns 24,030 shares of the company’s stock valued at $415,000 after acquiring an additional 1,406 shares during the last quarter. Public Employees Retirement System of Ohio lifted its position in shares of Entrada Therapeutics by 6.2% during the 4th quarter. Public Employees Retirement System of Ohio now owns 17,259 shares of the company’s stock valued at $298,000 after acquiring an additional 1,000 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Entrada Therapeutics by 152.5% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 35,750 shares of the company’s stock valued at $618,000 after acquiring an additional 21,594 shares during the last quarter. Finally, State of Wyoming acquired a new stake in shares of Entrada Therapeutics during the 4th quarter valued at $104,000. 86.39% of the stock is owned by institutional investors.

Insider Buying and Selling at Entrada Therapeutics

In other Entrada Therapeutics news, major shareholder Bioventures 2018 L.P. Mpm sold 22,935 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $20.77, for a total transaction of $476,359.95. Following the completion of the transaction, the insider now directly owns 4,402,849 shares of the company’s stock, valued at approximately $91,447,173.73. This trade represents a 0.52 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 7.59% of the stock is currently owned by corporate insiders.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.